Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
Gwenolé Loas, Pascal Le Corre
Abstract
The SARS-CoV-2 outbreak is characterized by the need of the search for curative drugs for treatment. In this paper, we present an update of knowledge about the interest of the functional inhibitors of acid sphingomyelinase (FIASMAs) in SARS-CoV-2 infection. Forty-nine FIASMAs have been suggested in the treatment of SARS-CoV-2 infection using in silico, in vitro or in vivo studies. Further studies using large-sized, randomized and double-blinded controlled clinical trials are needed to evaluate FIASMAs in SARS-CoV-2 infection as off-label therapy.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)In silicoIn vivoMedicineSphingomyelinCoronavirus disease 2019 (COVID-19)Clinical trialPharmacologyOutbreak2019-20 coronavirus outbreakVirologyBiologyInternal medicineDiseaseInfectious disease (medical specialty)BiochemistryCholesterolGeneBiotechnologySphingolipid Metabolism and SignalingLipid Membrane Structure and BehaviorPharmacological Receptor Mechanisms and Effects